SeerSEER +38.58%53 EBIT per Share is $-1.32 as of Mar. 2026. GuruFocus rates SEER with a GF Score™ of 53/100 and a GF Value™ of $2.20 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,174 Biotechnology companies, Seer ranks worse than 64.74% on this metric.
Seer's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.31.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.32.
During the past 3 years, the average EBIT per Share Growth Rate was 4.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 6.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Seer's EBIT per Share or its related term are showing as below:
SEER'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -55 Med: -11 Max: 14
Current: 4.5
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Seer was 14.00% per year. The lowest was -55.00% per year. And the median was -11.00% per year.
SEER's 3-Year EBIT Growth Rate is ranked worse than 64.74% of 1174
companies
in the Biotechnology industry
Industry Median: 15.4
vs SEER: 4.50
Seer's EBIT for the
three
months ended in Mar. 2026 was $-17.26 Mil.
Seer (NAS:SEER) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Seer EBIT per Share Related Terms
Seer EBIT per Share Historical Data
* Premium members only.
The historical data trend for Seer's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.32
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seer (SEER) has a EBIT per Share of $-1.32 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Seer and its competitors. According to the industry distribution chart, Seer ranks #760 out of 1174 companies in the Biotechnology industry, placing it in the top 64.7%.
Is Seer's EBIT per Share too high?
Seer's current EBIT per Share is $-1.32. Based on the distribution chart, Seer ranks #760 out of 1174 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Seer has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Seer's EBIT per Share compare to CSBR and RLYB?
According to the Biotechnology industry distribution chart, Seer ranks #760 out of 1174 companies for EBIT per Share. This places Seer in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,174 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Seer and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Seer's current EBIT per Share is $-1.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seer stock overvalued right now?
Based on GuruFocus' analysis, Seer (SEER) is currently considered Fairly Valued. The stock's GF Value™ is $2.20, compared to a current price of $2.25 — trading 2% above its estimated fair value. The current EBIT per Share is $-1.32. Seer's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Seer (SEER), the current EBIT per Share is $-1.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Seer (SEER) Overvalued in 2026?
Based on GuruFocus' analysis, Seer stock appears to be overvalued.
The current stock price of $2.25 is trading 2% above its estimated GF Value™ of $2.20.
GuruFocus considers Seer to be Fairly Valued.
Key valuation signals for SEER:
EBIT per Share: $-1.32
GF Value™: $2.20 vs. price of $2.25 (2% above fair value)
No single metric tells the full story. See the SEER stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.
53GF Score
Get the complete analysis for SEER
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SEER has been successfully added to your 
